Fierce Pharma
AUGUST 30, 2024
As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus. | With the nod, Emergent's vaccine joins Bavarian Nordic's Jynneos as approved protection options to address the continued outbreak in Africa, which was recently deemed a public health emergency.
Pharma IQ
AUGUST 30, 2024
Understand the potential of AI to unlock the comprehensive value of health data and transform the healthcare sector.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 30, 2024
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. | Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday.
MedCity News
AUGUST 30, 2024
Providers should carefully evaluate how different AI models can be strategically integrated to optimize the care management lifecycle and address the complex needs of their patients and populations, while at the same time prioritizing patient safety and ethical considerations. The post Overcoming the Challenges of Integrating AI in Care Management appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 30, 2024
Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer for now in its home country. | Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer in its home country for now thanks to doubts around patients’ overall survival.
MedCity News
AUGUST 30, 2024
In this month’s episode, Senior Reporter Katie Adams explored some of the executive moves and layoffs that recently occurred in the healthcare world. She also interviewed Graham Barnes, who just stepped into a new role as the CEO of Medically Home. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Graham Barnes, CEO of Medically Home appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 30, 2024
The speaker roster for the September 18 conference spans industry experts in cybersecurity, healthcare investment, AI for drug development, diagnostic testing, and more. The post Who is Speaking at MedCity INVEST Digital Health in Dallas? appeared first on MedCity News.
Fierce Pharma
AUGUST 30, 2024
Alnylam is circling the bases after walloping—in the words of chief medical officer Pushkal Garg M.D.—a “grand slam” with data that position its RNA silencer Amvuttra (vutrisiran) to potentially be | At the European Society of Cardiology conference in London, Alnylam presented positive data from the phase 3 HELIOS-B trial which assessed RNA silencer Amvuttra (vutrisiran) as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
MedCity News
AUGUST 30, 2024
Expanding the diversity of our mental health workforce is crucial, but it’s a long-term goal that won’t address the immediate needs we’re facing today. We need solutions now to bridge the gap between demand and access. The post Mental Healthcare in Underserved Populations is in Crisis and It’s Not Just a Provider Resource Problem appeared first on MedCity News.
Pharmaceutical Technology
AUGUST 30, 2024
US Congress labelled pharmacy benefit managers (PBMs) as ‘anticompetitive’; PBMs blame manufacturers for increasing pharmaceutical prices.
MedCity News
AUGUST 30, 2024
Through a new partnership, Hinge Health members receiving movement-based menopause support will also be able to access clinical care from Midi Health. The post Hinge Health, Midi Health Strike Partnership for Women Experiencing Menopause appeared first on MedCity News.
pharmaphorum
AUGUST 30, 2024
Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.
MedCity News
AUGUST 30, 2024
Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.
pharmaphorum
AUGUST 30, 2024
Troubled UK biotech ReNeuron will cancel its AIM listing, saying it has been unable to raise the funds it needs to bring it out of administration
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MedCity News
AUGUST 30, 2024
Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic. The post FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox appeared first on MedCity News.
Pharmaceutical Commerce
AUGUST 30, 2024
The latest news for pharma industry insiders.
MedCity News
AUGUST 30, 2024
Check out news from Oral Genome, BeMe Health, Noetik, and Vouched. The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the CD44 Antigen pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
pharmaphorum
AUGUST 30, 2024
BioMarin wields axe again, slashing 225 positions from its global workforce as it continues a major restructuring drive
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData’s report assesses the drugs in the Aromatase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
PharmExec
AUGUST 30, 2024
Submission is supported by results from the Phase III Vivacity-MG3 study, which demonstrated that nipocalimab, combined with standard care, significantly improved outcomes for patients with antibody-positive generalized myasthenia gravis.
Healthcare Success
AUGUST 30, 2024
As you might expect, our agency networks with lots of people in the financial world, including investment bankers and private equity firms. To capture today’s M&A trends and insights , I interviewed Andre Ulloa, a Partner and Executive Advisor at M&A Healthcare Advisors (MAHA), a boutique advisory firm and investment bank. Our podcast interview covered a lot of ground, including the basics—like the differences between finders, business brokers, advisors, and investment banks.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 39 drugs in development for Eosinophilic Esophagitis by 36 companies/universities/institutes. The top development phase for Eosinophilic Esophagitis is preclinical, with 14 drugs in that stage.
European Pharmaceutical Review
AUGUST 30, 2024
Researchers have developed an innovative synthesis method for pharmaceutical compounds that does not require the use of PFAS reagents. Caesium fluoride salt was used as alternative fluorine source. The approach resulted in a combination of various anions with a range of substrates which produced multiple fluorinated products with relevance to pharmaceutical syntheses, according to the team.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 85 drugs in development for Esophagitis by 74 companies/universities/institutes. The top development phase for Esophagitis is phase i, with 26 drugs in that stage.
pharmaphorum
AUGUST 30, 2024
The success of clinical trials depends on various factors beyond traditional clinical care, including social determinants of health (SDOH) like housing, health literacy, transportation, and social support. These factors can impact participant recruitment, retention, and the quality of data collected. In this webinar, panelists will explore how industry leaders are using non-clinical data to improve recruitment, retention, and evidence generation in clinical trials.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 88 drugs in development for Esophageal Diseases by 77 companies/universities/institutes. The top development phase for Esophageal Diseases is phase i, with 28 drugs in that stage.
PharmaTech
AUGUST 30, 2024
Ecolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.
Pharmaceutical Technology
AUGUST 30, 2024
GlobalData tracks 7 drugs in development for Peritoneal Tumor by seven companies/universities/institutes. The top development phase for Peritoneal Tumor is phase i, with three drugs in that stage.
PharmExec
AUGUST 30, 2024
Ecolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
279 
Let's personalize your content